BOLD 100
Alternative Names: BOLD 100; IT-139; KP 1339; NKP-1339Latest Information Update: 07 Jun 2024
At a glance
- Originator Medical University of Vienna; Queens University Belfast; University of Vienna
- Developer Bold Therapeutics; Georgetown University; Hana Pharm; Intezyne; University of Ottawa
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA inhibitors; Molecular chaperone GRP78 protein inhibitors; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Pancreatic cancer
- Preclinical COVID 2019 infections; Triple negative breast cancer
- No development reported Solid tumours
Most Recent Events
- 03 Jun 2024 Efficacy and adverse events data from a phase Ib/IIa trial in Biliary cancer and Gastric cancer released by Bold Therapeutics
- 03 Jun 2024 Bold Therapeutics plans a phase II randomised trial for Colorectal cancer (Second-line therapy or greater, Combination therapy) in multiple countries (IV)
- 05 Apr 2024 Pharmacodynamics data from the preclinical trial in Adenocarcinoma released by Bold Therapeutics